Various other multikinase inhibitors in NSCLC are designed against the vascular endothelial growth factor receptor, platelet‐derived growth factor receptor, B‐Raf, and RAF proto‐oncogene serine/threonine‐protein kinase (c‐Raf) which serve as potential targets.117 Studies have also been undertaken to use HSP90 inhibitors, which is a molecular chaperone in NSCLC. Here, RAF1 is linked to non-small cell lung carcinoma.